Of all the articles previously referred to here in the August Immunology Today, this one (I think not mentioned) is a good primer for newcomers. Table 1 "A selection of naked mAb currently in clinical development", in part based on data from r van de Broek, tells quite a story.
--Wilder
Immunol Today 2000 Aug;21(8):403-10 Books, LinkOut
Clinical trials of antibody therapy.
Glennie MJ, Johnson PW
Tenovus Research Laboratory, The Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton, UK SO16 6YD.
[Medline record in process]
Much of the 25 years since Kohler and Milstein first described making monoclonal antibodies (mAbs) has been spent trying to develop these reagents to treat human disease. Until recently, progress has been frustratingly slow and by 1994 only one mAb, anti-CD3 (OKT3), had been licensed for clinical use. In the past five years, however, the situation has changed dramatically, with numerous mAbs now showing clinical potential, and a further seven approved for human treatment. Furthermore, all indications are that this upward trend will continue, with a quarter of all new biological products currently undergoing clinical development being antibody based.
PMID: 10916144, UI: 20377422 |
